Research Paper Volume 13, Issue 17 pp 21102—21121
Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
Figure 3. Cell-cycles are arrested at G1/G0-phase in the MCL cell lines after being treated with BGB-3111. Cell cycles of Jeko-1 (A) Rec-1 (B) and Z138 (C) treated with BGB-3111 at the doses of 0 μM, 1 μM, 2 μM, and 3 μM for 48 h. The cell percentage of the cell cycle was detected using flow cytometry.